Reactivation of hepatitis B virus replication due to cytotoxic therapy: A five-year prospective study

Tumori

Volumn 98, Issue 2, 2012, Pages 220-224

  Francisci, Daniela ^a   Falcinelli, Flavio ^a   Schiaroli, Elisabetta ^a   Capponi, Monia ^a   Belfiori, Barbara ^a   Cecchini, Enisia ^a   Baldelli, Franco ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

HBV; Hematological malignancies; Reactivation; Rituximab

Indexed keywords

ADEFOVIR; BIOLOGICAL MARKER; CYTOTOXIC AGENT; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; RITUXIMAB; TENOFOVIR; ADENINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PHOSPHONIC ACID DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC LEUKEMIA; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG MONITORING; DRUG SAFETY; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HODGKIN DISEASE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RISK ASSESSMENT; SIDE EFFECT; SYSTEMIC THERAPY; VIRUS INHIBITION; VIRUS REACTIVATION; VIRUS REPLICATION; BLOOD; DRUG COMBINATION; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; RECURRENT DISEASE; TREATMENT OUTCOME; VIRUS ACTIVATION;

ADENINE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84864883806     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1088.11933     Document Type: Article

References (28)

1. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med, 96: 447-449, 1982. (Pubitemid 12139868)
2. Xunrong L, Yan AW, Liang R, Lau GK: Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management. Rev Med Virol, 11: 287-299, 2001. (Pubitemid 33009970)
3. Yeo W, Johnson PJ: Diagnosis, prevention and management of hepatitis B reactivation during anticancer therapy. Hepatology, 43: 209-220, 2006.
4. Kusumoto S, Tanaka Y, Mizokami M, Ueda R: Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol, 90: 13-23, 2009.
5. Dervite I, Hober D, Morel P: Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med, 344: 68-69, 2001. (Pubitemid 32064857)
6. Dhédin N, Douvin C, Kuentz M, Saint Marc MF, Reman O, Rieux C, Bernaudin F, Norol F, Cordonnier C, Bobin D, Metreau JM, Vernant JP: Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation, 66: 616-619, 1998. (Pubitemid 28433844)
7. Sugauchi F, Tanaka Y, Kusumoto S, Matsuura K, Sugiyama M, Kubarnov F, Ueda R, Mizokami M: Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol, 83: 412-418, 2011.
8. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM: Fatal reactivation of hepatitis B post chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma, 46: 1085-1089, 2005. (Pubitemid 40975032)
9. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK: Kinetics and risk of de novo hepatitis B infection in HBsAg negative patients undergoing cytotoxic chemotherapy. Gastroenterology, 131: 59-68, 2006. (Pubitemid 44015749)
10. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KL, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ: Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol, 22: 927-934, 2004. (Pubitemid 41103605)
11. Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, Gerlich WH, Thiel E: Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood, 102: 1930, 2003. (Pubitemid 37022596)
12. Kusumoto S, Tanaka Y, Ueda R, Mizokami M: Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol, 46: 9-16, 2011.
13. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346: 235-242, 2002. (Pubitemid 34438862)
14. Iannitto E, Minardi V, Calvaruso G, Mulè A, Ammatuna E, Di Trapani R, Ferraro D, Abbadessa V, Craxì A, Di Stefano R: Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haemathol, 74: 254-258, 2005. (Pubitemid 40278496)
15. Calabrese LH, Zein NN, Vassilopoulos D: Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis, 65: 983-989, 2006. (Pubitemid 44133258)
16. Dienstag JL: Hepatitis B virus infection. N Engl J Med, 359: 1486-1500, 2008.
17. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol, 62: 299-307, 2000.
18. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G: Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumors. Br J Cancer, 81: 69-74, 1999. (Pubitemid 29415493)
19. Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A, Chionne P, Madonna E, Cotichini R, Barbui A, De Renzo A, Dore F, Iannitto E, Liso V, Martino B, Montanaro M, Pagano L, Musto P, Rapicetta M: High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica, 91: 554-557, 2006.
20. Targhetta C, Cabras MG, Angelucci E: Risk of HBV liver disease in isolated antiHBc patients receiving immuno-chemotherapy for non Hodgkin lymphoma. Haematologica, 93: e66, 2008.
21. European Association for the Study of the Liver: EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol, 50: 227-242, 2009.
22. Tran TT, Rakoski MO, Martin P, Poordad F: Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Aliment Pharmacol Ther, 31: 240-246, 2009.
23. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagiuoli S, Grossi P, Lampertico P, Meliconi R, Mangia A, Puoti M, Raimondo G, Smedile A, Italian Association for the Study of the Liver: Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis, 39: 397-408, 2007. (Pubitemid 46508732)
24. Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, Zon RT, Wong SL: American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol, 28: 3199-3202, 2010.
25. Stroffolini T, Almasio PL, Sagnelli E, Mele A, Gaeta GB: Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study. J Med Virol, 81: 1999-2006, 2009.
26. Ji D, Cao J, Hong X, Li J, Wang J, Chen F, Wang C, Zou S: Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol, 85: 243-250, 2010.
27. Carrol MB: The impact of biologic response modifiers on hepatitis B virus infection. Expert Opin Biol Ther, 11: 533-544, 2011.
28. Morisco F, Castiglione F, Rispo A, Stroffolini T, Vitale R, Sansone S, Granata R, Orlando A, Marmo R, Riegler G, Vecchi M, Biancone L, Caporaso N: Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis, 43 (Suppl 1): 40-48, 2011.